2026-10-14T21:17:33Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34031150 2026-09-30T09:57:27Z category_7 category_16 category_19 category_21 category_45 category_46 category_734 category_132 category_134 portal_87 item_type_6 month_year_09_2026

Effectiveness of switching from reference adalimumab to biosimilar adalimumab-atto in patients with chronic non-infectious uveitis Ying Qian (482851) Damien C. Rodger (25143029) Fang Niu (316587) Thomas Delate (558504) Rita L. Hui (25143032) Medicine Physiology Pharmacology Biotechnology Sociology Immunology Biological Sciences not elsewhere classified Infectious Diseases Virology Uveitis chronic noninfectious uveitis adalimumab biosimilar adalimumab-atto <p>Limited real-world studies have evaluated outcomes after switching treatment from a reference product (RP) to a biosimilar product in noninfectious uveitis (NIU). The objective of this real-world study was to assess the outcomes of switching from RP adalimumab to biosimilar adalimumab-atto in the United States.</p> <p>This retrospective pre-post study included adults with NIU who were stable on RP adalimumab, switched to adalimumab-atto, and followed for up to 6 months. Outcomes included the use of systemic and local high-dose corticosteroids, analyzed using interrupted time series analyses, and changes in visual acuity among patients with both pre- and post-switch acuity measurements.</p> <p>One hundred and ninety patients were included, with a mean age of 50.5 ± 16.0 years, 61.1% female, and a mean disease duration of 6.5 ± 6.3 years prior to switching. There was no statistically significant trend in usage of either systemic or local high-dose corticosteroid after the switch (<i>p</i> = 0.33 and <i>p</i> = 0.36, respectively). There was no change in vision acuity (<i>n</i> = 110, <i>p</i> = 0.61).</p> <p>The lack of change in systemic or local high-dose corticosteroid use following the switch from RP adalimumab to adalimumab-atto suggests that the switch may be effective and safe in adult patients with NIU.</p> 2026-09-30T09:57:27Z Text Journal contribution 10.6084/m9.figshare.34031150.v1 https://figshare.com/articles/journal_contribution/Effectiveness_of_switching_from_reference_adalimumab_to_biosimilar_adalimumab-atto_in_patients_with_chronic_non-infectious_uveitis/34031150 CC BY 4.0